OrganiGram Holdings Inc (CVE:OGI) Quiet Earnings Response Is a Positive Sign


OrganiGram Holdings Inc (CVE:OGI) (OTCMKTS:OGRMF) (FRA: 0OG) earnings report today has been met with collective tepidness, from a price action perspective. Shares drifted lower after the attempted morning gap-up, with about 60% of the day’s trading volume occurring within the session’s first 15-minutes (as of 1:45pm). Investors puzzled by the response shouldn’t be, and we’re about to tell you why.

First, let’s recap OrganiGram’s solid earnings report, where it becomes among the first pure-play cannabis company to post a black Net Income number. That’s a significant milestone which shouldn’t be flippantly overlooked.

Three-months ended
February 28



Six-months ended

February 28



(in $000 except EPS)





Gross sales

$ 3,219

$ 1,445


$ 5,906

$ 3,675


Sales recovery (return)

$ 469

$ (2,026)


$ 469

$ (2,026)


Net sales2

$ 3,689

$ (581)


$ 6,375

$ 1,650


Cost of sales (incl. indirect production)

$ (1,550)

$ (3,029)


$ (3,340)

$ (3,808)


Gross margin (excluding FV adjustment)

$ 2,138

$ (3,610)


$ 3,035

$ (2,158)


FV adjust. on bio assets and inventories

$ 4,384

$ (367)


$ 5,106

$ (1,056)


Gross margin

$ 6,523

$ (3,977)


$ 8,141

$ (3,214)


Net income (loss)

$ 1,078

$ (5,755)


$ (324)

$ (6,511)


EPS (basic)

$ 0.009

$ (0.059)


$ (0.003)

$ (0.071)


EPS (diluted)

$ 0.008

$ (0.059)


$ (0.003)

$ (0.071)


Sales of (in thousands):

Dried cannabis flower (gr)







Cannabis oil sold (ml)







Record net sales were booked for both Q2 and six-months ended February 28. Dried marijuana flower and refined cannabis oil both increased, with the latter really taking off: cannabis oil sales rose 450% for the six month period on a YoY basis. Record yields per plant were experienced in Q2, with the company projecting new lows in production costs per gram in Q3. In fact, just about every important metric saw soaring growth, from net sales to medical patient enrollment to cost of sales.

And of course the company delivered on the biggest metric of all: positive Net Income of $1.1 million dollars after all the bills were paid. 

Given that OrganiGram is executing their business model seamlessly through the still-early innings of cannabis sector pre-eminence, why have investors reacted with a collective shrug? The short answer is, investors don’t care about the profitability metrics. And that’s exactly why OrganiGram’s future is so bright.

When investors start reacting to earnings numbers, it’s a telltale sign of a maturing sector. Generally, analysts will publish EPS expectations and have internal “whisper” numbers which guide institutional flows post-results. Net earnings, margins, sales, etc. become the drivers of share price instead of hope, dreams and what could-be.

With investor unresponsiveness to today’s OGI report, it’s abundantly clear that the company is still in the promise stage, where forward growth is viewed as the ultimate arbiter of OrganiGram’s share price—not current results. In other words, investors are less focused on the now, and more focused on the future, which is where early-stage growth investors want to be positioned.

Rest assured, they’ll be a time where the OGI (and cannabis sector) growth rates start slowing, and investors will look more towards quarterly EPS, dividends, and free cash flow for direction. That endgame ultimately resides somewhere five or seven or ten years down the line. That’s a positive and natural expectation of the capital markets investment cycle.

But for investors hunting for the proverbial “10-bagger”, focus on execution rather than post-earnings reaction should be the defining guidepost. In the early stages, it’s the execution part which will sink 80% of the industry, gradually siphoning investment capital to the survivors. Increasingly, OrganiGram looks to be a part of the winning side.

While the black NI number is nice, it isn’t the meaningful takeaway of today’s earnings release. Hands down, it was execution—whether the market realizes it or not.

OrganiGram Holdings CEO Greg Engel talks about today’s earnings release and more with Midas Letter CEO James West

Technical Take

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.